Lead discovery biotech explores structure based drug discovery on membrane protein targets

Michael Hennig, CEO of lead discovery company leadXpro will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event will take place on 27 – 28 March 2017 in Central London.

With a focus new developments and advancements on structure based drug discovery on membrane protein targets, his presentation explores
• why structure based drug discovery for soluble proteins is routinely used but transmembrane proteins are still challenging
• progress in membrane protein expression, purification and solubilization as well as the use of serial crystallography at synchroton and Free Electron Laser
• recent developments on single particle cryo-electron microscopy for high-res structure determination
• an outline of opportunities for hit and lead discovery using information derived from biophysical methods and structures of membrane protein drug targets

In the lead up to the event, Michael mentioned “More and more challenging biological mechanisms and drug targets are tackled successfully in the pharmaceutical industry. There are many small innovations, technological advances, more concerted efforts that really make a difference. I am impressed by the advances structure-based drug discovery has made in the past years.
Drug discovery on more and more drug targets, for example membrane proteins, can benefit from structural information and application of biophysical methods to investigate ligand to drug target interaction. This helps to create more specific small molecule drug molecules with less side effects and better efficacy.”

Michael will be speaking on Day 1 of the conference and joins lead decision-makers and industry innovators from AstraZeneca, Sanofi, Takeda, Merck Serono, AbbVie, GSK, Johnson & Johnson, UCB Pharma, Eli Lilly and more. A full list of speakers can be found on http://www.drug-discovery.co.uk/openpr.

SMi’s Drug Discovery conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

The event will also feature two post-conference workshops on new approaches in lead generation and applications of physicochemical and biomimetic properties in early drug discovery.

For more details about the conference and registration information, visit www.drug-discovery.co.uk/openpr.

DRUG DISCOVERY
27 – 28 MARCH 2017
Holiday Inn Kensington Forum
www.drug-discovery.co.uk/openpr

---end ---

Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Fateja Begum at fbegum@smi-online.co.uk. For media queries please contact Honey de Gracia at hdegracia@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

1 Westminster Bridge Road, SE1 7XW

This release was published on openPR.